2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-N0832
    L-Histidine 71-00-1
    L-Histidine is an essential amino acid for infants. L-Histidine is an inhibitor of mitochondrial glutamine transport.
    L-Histidine
  • HY-30008
    Cycloleucine 52-52-8 ≥98.0%
    Cycloleucine is a specific inhibitor of S-adenosyl-methionine mediated methylation. Cycloleucine is antagonist of NMDA receptor associated glycine receptor, with a Ki of 600 μM. Cycloleucine is also a competitive inhibitor of ATP: L-methionine-S-adenosyl transferase in vitro. Cycloleucine has anxiolytic and cytostatic effects.
    Cycloleucine
  • HY-16950A
    (E/Z)-4-Hydroxytamoxifen 68392-35-8 ≥99.0%
    (E/Z)-4-Hydroxytamoxifen (Afimoxifene) is a racemic compound of (Z)-4-Hydroxytamoxifen and (E)-4-Hydroxytamoxifen isomers. (E/Z)-4-Hydroxytamoxifen is a selective estrogen receptor modulator with mixed estrogenic and antiestrogenic activity, which is also an active metabolite of Tamoxifen (HY-13757A). (E/Z)-4-Hydroxytamoxifen is an agonist of the G protein-coupled estrogen receptor (GPER) with relatively low affinity (100-1000 nM). (E/Z)-4-Hydroxytamoxifen is promising for research of cyclical mastalgia, such as breast pain, tenderness, and nodularity.
    (E/Z)-4-Hydroxytamoxifen
  • HY-10838
    GW 501516 317318-70-0 99.27%
    GW 501516 (GW 1516) is a PPARδ agonist with an EC50 of 1.1 nM.
    GW 501516
  • HY-101455
    CDN1163 892711-75-0 99.90%
    CDN1163 is an allosteric sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) activator that improves Ca2+ homeostasis. CDN1163 attenuates diabetes and metabolic disorders.
    CDN1163
  • HY-P0203
    α-CGRP (mouse, rat) 83651-90-5 99.80%
    α-CGRP (mouse, rat), a neuropeptide (calcitonin gene-related peptide (CGRP)) mainly expressed in neuromuscular junction, is a potent vasodilator. α-CGRP (mouse, rat) can lead to a fall in blood pressure and an increase in heart rate by peripheral administration, also relax colonie smooth muscle. α-CGRP (mouse, rat) has the potential in cardiovascular, pro-inflammatory, migraine and metabolic studies.
    α-CGRP (mouse, rat)
  • HY-10863
    Anandamide 94421-68-8 ≥99.0%
    Anandamide is an endocannabinoid. Anandamide modulates both neuronal and immune functions through two protein-coupled cannabinoid receptors (CB1 and CB2). Anandamide can activate numerous other receptors like PPARS, TRPV1, and GPR18/GPR55. Anandamide also has potential anti-fungal and anti-inflammatory activities. Anandamide can be used for the research of Alzheimer’s disease (AD) and ulcerative colitis.
    Anandamide
  • HY-108341
    PF-06424439 1469284-78-3 99.89%
    PF-06424439 is an oral, potent and selective imidazopyridine diacylglycerol acyltransferase 2 (DGAT2) inhibitor with an IC50 of 14 nM. PF-06424439 is slowly reversible, time-dependent inhibitor, which inhibits DGAT2 in a noncompetitive mode with respect to the acyl-CoA substrate.
    PF-06424439
  • HY-W018392
    Mono-(2-ethylhexyl) phthalate 4376-20-9
    Mono-(2-ethylhexyl) phthalate (MEHP) is a major bioactive metabolite of diethylhexyl phthalate (DEHP). Mono-(2-ethylhexyl) phthalate can promote fatty acid synthesis in hepatocytes by regulating the expression of relevant genes and proteins, contributing to non-alcoholic fatty liver disease (NAFLD).
    Mono-(2-ethylhexyl) phthalate
  • HY-17408
    Mevastatin 73573-88-3 99.46%
    Mevastatin (Compactin) is a first HMG-CoA reductase inhibitor that belongs to the statins class. Mevastatin is a lipid-lowering agent, and induces apoptosis, arrests cancer cells in G0/G1 phase. Mevastatin also increases endothelial nitric oxide synthase (eNOS) mRNA and protein levels. Mevastatin has antitumor activity and has the potential for cardiovascular diseases treatment.
    Mevastatin
  • HY-110063
    4-IPP 41270-96-6 99.46%
    4-IPP (4-Iodo-6-phenylpyrimidine) is a specific suicide substrate and irreversible inhibitor of macrophage migration inhibitory factor (MIF).
    4-IPP
  • HY-P1944A
    Apelin-13 TFA 98.98%
    Apelin-13 TFA is an endogenous ligand for the G-protein coupled receptor angiotensin II protein J (APJ), activating this G protein-coupled receptor with an EC 50 value of 0.37 nM. Apelin-13 TFA has vasodilatory and antihypertensive effects. Apelin-13 TFA also can be used for researching type 2 diabetes and metabolic syndrome.
    Apelin-13 TFA
  • HY-100111
    GLX351322 835598-94-2 99.48%
    GLX351322 is an inhibitor of NADPH oxidase 4 (Nox4), and inhibits hydrogen peroxide production from NOX4-overexpressing cells with an IC50 of 5 μM.
    GLX351322
  • HY-125857
    Cytochrome C 9007-43-6 ≥99.0%
    Cytochrome C is a multi-functional enzyme involving in life and death decisions of the cell. Cytochrome C is essential in mitochondrial electron transport and intrinsic type II apoptosis.
    Cytochrome C
  • HY-14136
    Rimonabant 168273-06-1 99.52%
    Rimonabant (SR141716) is a highly potent, brain penetrated and selective central cannabinoid receptor (CB1) antagonist with a Ki of 1.8 nM. Rimonabant (SR141716) also inhibits Mycobacterial membrane protein Large 3 (MMPL3).
    Rimonabant
  • HY-107454
    OSS_128167 887686-02-4 98.63%
    OSS_128167 is a potent selective sirtuin 6 (SIRT6) inhibitor with IC50s of 89 μM, 1578 μM and 751 μM for SIRT6, SIRT1 and SIRT2, respectively. OSS_128167 has anti-HBV activity that inhibits HBV transcription and replication. OSS_128167 has anti-cancer, anti-inflammation and anti-viral effects.
    OSS_128167
  • HY-B1068
    Tyloxapol 25301-02-4
    Tyloxapol is a nonionic liquid polymer of the alkyl aryl polyether alcohol type, used as a surface active stabilizer. Tyloxapol is used to induce hyperlipidemia in animals.
    Tyloxapol
  • HY-138620
    MCU-i4 371924-24-2 99.87%
    MCU-i4 blocks the IP3-dependent mitochondrial Ca2+-uptake, maintaining the gatekeeping role of their target.
    MCU-i4
  • HY-19805
    STO-609 52029-86-4 ≥98.0%
    STO-609 is a selective and cell-permeable inhibitor of the Ca2+/calmodulin-dependent protein kinase kinase (CaM-KK), with Ki values of 80 and 15 ng/mL for recombinant CaM-KKα and CaM-KKβ, respectively. STO-609 inhibits AMP-activated protein kinase kinase (AMPKK) activity in HeLa cell lysates with an IC50 ~0.02 g/ml.
    STO-609
  • HY-17468
    Bumetanide 28395-03-1 99.95%
    Bumetanide (Ro 10-6338; PF 1593), a highly potent loop diuretic, is a Na+-K+-Cl+ cotransporter (NKCC) blocker. Bumetanide is a selective NKCC1 inhibitor, but also inhibits NKCC2, with IC50s of 0.68 μM and 4.0 μM for hNKCC1A and hNKCC2A, respectively.
    Bumetanide
Cat. No. Product Name / Synonyms Application Reactivity